IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMIZED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN

被引：0
|
作者：
Hiddemann, W. [1 ]
Barbui, A. M. [2 ]
Albendea, M. A. Canales [3 ]
Cannell, P. K. [4 ]
Collins, G. P. [5 ]
Duerig, J. [6 ]
Forstpointner, R. [1 ]
Herold, M. [7 ]
Hertzberg, M. [8 ]
Klanova, M. [9 ,10 ,11 ]
Radford, J. A. [12 ,13 ]
Tobinai, K. [14 ]
Burciu, A. [15 ]
Fingerle-Rowson, G. R. [11 ]
Nielsen, T. [11 ]
Wolbers, M. [16 ]
Marcus, R. E. [17 ]
机构：
[1] Ludwig Maximilians Univ Munchen, Dept Med 3, Munich, Germany
[2] Azienda Osped Papa Giovanni XXIII, Dept Hematol, Bergamo, Italy
[3] Hosp Univ la Paz, Dept Med, Madrid, Spain
[4] Fiona Stanley Hosp, Dept Haematol, Murdoch, WA, Australia
[5] Churchill Hosp, Oxford Canc & Haematol Ctr, Dept Clin Haematol, Oxford, England
[6] Univ Klinikum Essen, Med Fac Haematol, Essen, Germany
[7] HELIOS Klinikum Erfurt, Ctr Oncol, Erfurt, Germany
[8] Prince Wales Hosp, Dept Haematol, Sydney, NSW, Australia
[9] Charles Univ Prague, Fac Med 1, Gen Hosp, Prague, Czech Republic
[10] Charles Univ Prague, Inst Pathol Physiol, Prague, Czech Republic
[11] F Hoffmann La Roche Ltd, Pharma Dev Clin Oncol, Basel, Switzerland
[12] Univ Manchester, Manchester, Lancs, England
[13] Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[14] Natl Canc Ctr, Dept Hematol, Tokyo, Japan
[15] F Hoffmann La Roche Ltd, Pharma Dev Safety & Risk Management, Basel, Switzerland
[16] F Hoffmann La Roche Ltd, Pharma Dev Biometr Biostat, Basel, Switzerland
[17] Kings Coll Hosp London, Dept Haematol, London, England
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S775
引用
收藏
页码：314 / 314
页数：1
相关论文
共 50 条
  • [41] Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study
    Gibiansky, Ekaterina
    Gibiansky, Leonid
    Buchheit, Vincent
    Frey, Nicolas
    Brewster, Michael
    Fingerle-Rowson, Gunter
    Jamois, Candice
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (09) : 1935 - 1945
  • [42] Preliminary safety, pharmacokinetics, and pharmacodynamics of duvelisib plus rituximab or obinutuzumab in patients with previously untreated CD20+follicular lymphoma.
    Casulo, Carla
    Jacobsen, Eric D.
    Van Eygen, Koen
    Holmes, Houston Eccleston
    Lemmens, Jan P.
    Allen, Kerstin
    Steelman, Lori
    Campbell, Veronica
    Nevejans, Jylle
    Pearlberg, Joseph
    Goy, Andre
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] A Phase 2 Trial of Extended Induction Epratuzumab and Rituximab for Previously Untreated Follicular Lymphoma: CALGB 50701
    Grant, Barbara W.
    Jung, Sin-Ho
    Johnson, Jeffrey L.
    Kostakoglu, Lale
    Hsi, Eric
    Byrd, John C.
    Jones, Jeffrey
    Leonard, John P.
    Martin, S. Eric
    Cheson, Bruce D.
    CANCER, 2013, 119 (21) : 3797 - 3804
  • [44] Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103
    Ujjani, Chaitra S.
    Jung, Sin-Ho
    Pitcher, Brandelyn
    Martin, Peter
    Park, Steven I.
    Blum, Kristie A.
    Smith, Sonali M.
    Czuczman, Myron
    Davids, Matthew S.
    Levine, Ellis
    Lewis, Lionel D.
    Smith, Scott E.
    Bartlett, Nancy L.
    Leonard, John P.
    Cheson, Bruce D.
    BLOOD, 2016, 128 (21) : 2510 - 2516
  • [45] Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study
    Hong, Xiaonan
    Song, Yuqin
    Shi, Yuankai
    Zhang, Qingyuan
    Guo, Wei
    Wu, Gang
    Li, Junmin
    Feng, Jifeng
    Kinkolykh, Anastasiia
    Knapp, Andrea
    Lin, Tongyu
    CHINESE MEDICAL JOURNAL, 2022, 135 (04) : 433 - 440
  • [46] Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study
    Hong Xiaonan
    Song Yuqin
    Shi Yuankai
    Zhang Qingyuan
    Guo Wei
    Wu Gang
    Li Junmin
    Feng Jifeng
    Kinkolykh Anastasiia
    Knapp Andrea
    Lin Tongyu
    中华医学杂志英文版, 2022, 135 (04) : 433 - 440
  • [47] HEALTH-RELATED QUALITY OF LIFE RESULTS FROM THE PHASE III GALLIUM STUDY OF OBINUTUZUMAB-BASED AND RITUXIMAB-BASED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED INDOLENT NON-HODGKIN LYMPHOMA
    Davies, A.
    Trask, P.
    Demeter, J.
    Florschuetz, A.
    Haenel, M.
    Hong, X.
    Kinoshita, T.
    Pettengell, R.
    Quach, H.
    Robinson, S.
    Sadullah, S.
    Sancho, J. -M.
    Udvardy, M.
    Witzens-Harig, M.
    Rufibach, K.
    Zeuner, H.
    Unterhalt, M.
    HAEMATOLOGICA, 2017, 102 : 190 - 191
  • [48] Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia
    Byrd, John C.
    Flynn, Joseph M.
    Kipps, Thomas J.
    Boxer, Michael
    Kolibaba, Kathryn S.
    Carlile, David J.
    Fingerle-Rowson, Guenter
    Tyson, Nicola
    Hirata, Jamie
    Sharman, Jeff P.
    BLOOD, 2016, 127 (01) : 79 - 86
  • [49] Prospective Randomized Phase 2 Study of Acalabrutinib plus Obinutuzumab or Venetoclax in Previously Untreated CLL
    Kittai, Adam S.
    Huang, Ying
    Bhat, Seema A.
    Grever, Michael R.
    Suresh, Swetha
    Lozanski, Gerard
    Moran, Mollie
    Nussbaum, Megan
    Woyach, Jennifer A.
    Rogers, Kerry A.
    BLOOD, 2024, 144
  • [50] Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA-2).
    Hardin, Colin
    Gray, Carl
    Novelli, Silvana
    Hacibekiroglu, Tuba
    Yagci, Munci
    Birhiray, Ruemu Ejedafeta
    Risal, Ashish
    Namuduri, Manjusha
    Cai, Jingxian
    Ufkin, Melanie
    Zhu, Min
    Mukherjee, Sushmita
    Brouwer-Visser, Jurriaan
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth R.
    Iskierka-Jazdzewska, Elzbieta
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345